Oral Probiotic

Asher Health Oral Probiotic is a chewable tablet with a mild, minty flavor that contains:

BLIS K12 (S. salivarius) 2 + billion CFU per serving

BLIS M18 (S. salivarius) 2 + billion CFU per serving

Non GMO, Animal ang Gluten Free, Sugar Free, Magnesium Stearate Free, Desiccant Lined, Moisture Absorbing Activ-Polymer® Boite, Oxyfree® Absorber (Removes Oxygen During Storage)

Other Ingredients: Xylitol, Natural Flavors, (Wintergreen and Peppermint) Microcrystaline Cellulose (Plant Fiber), Stearic Acid, Silicon Dioxide, Stevia Rebaudiana Leaf Extract.

Oxyfree® Absorber is a registered trademark of Sorbetech International, LLC BLIS K12® and BLIS M18® are registered trademarks of BLIS Technologies Limited. Activ-Polymer™ is a trademark of CSP Technologies.

BLIS K12®: Targets the bad bugs that cause infections such as tonsillitis, pharyngitis, strep throat, and ear infections.

K12 triggers specific cells in the mouth to stimulate the body's immune system and protects the ears, nose, mouth, and throat against infection. Research shows children with S. salivarius K12 have a 50 percent less chance of the strep throat bacteria and may experience fewer ear infections.

BLIS M18®  Targets the bad bugs that cause gum disease and plaque build-up in your teeth. BLIS M18 supports overall oral health. It helps protect against cavities and tooth decay as well as helps prevent acid erosion caused by acidic foods.

Both K12 and M18 have been proven safe for adults and children and are free from side effects.

More Info:

Strep throat and ear infections are among the most common reasons for acute doctor visits and patients are often prescribed antibiotics. Not only can use and overuse of antibiotics lead to resistance, it can lead to other systemic side effects as antibiotics also kill our body’s “good bacteria”. Studies on ways to prevent and treat these acute infections and find prophylactic solutions are being explored. One study published by the International Journal of General Medicine showed the “efficacy of K12 on the prevention of pharyngo-tonsillar infections, the decrease in the use of antibiotics, and the improvement of the overall quality-of-life was confirmed, with a decreased number of absences from school and fewer patients undergoing surgery.” More details on the study below:

Methods: We enrolled 82 children, including 65 with and 17 without a recent diagnosis of recurrent oral streptococcal pathology. Of those with recurrent pathology, 45 were treated daily for 90 days with an oral slow-release tablet containing five billion colony-forming units of S. salivarius K12 (Bactoblis®), and the remaining 20 served as an untreated control group. The 17 children without a recent diagnosis of recurrent oral pathology were used as an additional control group. After 90 days of treatment, a 6-month follow-up period without treatment was included to evaluate a possible persistent protective role for the previously administered product. Results: The 41 children who completed the 90-day course of Bactoblis showed a reduction in their episodes of streptococcal pharyngeal infection (about 90%) and/or acute otitis media (about 40%), calculated by comparing infection rates in the previous year. The 90-day treatment also reduced the reported incidence of pharyngeal and ear infections by about 65% in the 6-month follow-up period during which the product was not administered. Subjects tolerated the product well, with no side effects or dropouts reported. Conclusion: Prophylactic administration of S. salivarius K12 to children with a history of recurrent oral streptococcal pathology reduced episodes of streptococcal pharyngeal infections and/or tonsillitis as well as episodes of acute otitis media (ear infections).

In longer term follow up studies, results indicated that prior use of the product provided durable protection against oral streptococcal pathology and acute otitis media, with about 65% reduction compared with controls. This study has several limitations, in that it is not randomized nor placebo-controlled, and was also not blinded. Furthermore, it was carried out in a relatively small number of children with recurrent oral streptococcal pathology but not specifically with recurrent acute otitis media, with episodes of the latter only being an endpoint. However, in spite of these limitations, the results demonstrate for the first time that use of S. salivarius K12, an oral probiotic, can reduce the incidence of bacterial throat and ear infections in children with a history of recurrent oral streptococcal infection.

Read full article here: https://www.tandfonline.com/doi/full/10.2147/IJGM.S168209

This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.